Navigation Links
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Date:5/16/2008

24-hour diastolic ambulatory blood pressure and mean seated office systolic and diastolic blood pressure as well as a number of other endpoints.

Investor event at ASH

Pharmacopeia will host a meeting for investors today, Friday, May 16th at 7:00am CDT (8:00am EDT) to review the Phase 2a study results from its PS433540 program, including a presentation by Joel Neutel, M.D., the study's lead investigator. A live webcast and 90-day archive of the presentation can be accessed on the Investors section of the company's website at http://www.pharmacopeia.com.

About PS433540

PS433540 is the first and only blood pressure product candidate in a new class of antihypertensives known as Dual Acting Receptor Antagonists (DARAs). PS433540 is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540 possesses two clinically validated mechanisms of action in a single molecule. There is preclinical and initial clinical data suggesting that compared to either mechanism alone, simultaneously blocking angiotensin II and endothelin 1 at their respective receptors, AT1 and ETA, may provide an improved treatment option for several cardiovascular diseases. Because PS433540 is highly selective for the AT1 and ETA receptors it is able to block the blood pressure-raising actions of angiotensin and endothelin when they bind to these receptors.

About Pharmacopeia

Pharmacopeia is a clinical development stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics to address significant medical needs. The company has a broad portfolio of clinical and preclinical candidates under development internally or by partners including eight clinical compounds in Phase 2 or Phase 1 development addressing multiple indications including hypertension, diabetic nephropathy, muscle wasting, inflammation and respiratory disease. The compa
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pharmacopeia Announces Upcoming Late-Breaker Presentation of Phase 2a Results for Its First-in-Class Investigational DARA Compound, PS433540
2. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
3. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
7. Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Calif., July 31, 2014 STAAR Surgical Company ... and marketer of implantable lenses and delivery systems for ... ended July 4, 2014 of $20.0 million, a 10% ... of 2013. On a constant currency basis, revenues grew ... the second quarter of 2013.  The effect of foreign ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
(Date:7/31/2014)... -- UBM Medica US announces that Cancer Network ... exclusive slide shows dealing with communication in the oncology ... Cancer Network, the online home ... and podcasts about the latest clinical findings. Among the ... , End-of-life care is challenging for even the most ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6
... Imaging announced today that it has received FDA 510(k) ... Analyzer® System to assess coronary branch vessels in addition ... artery disease (CAD). The clearance is the third for ... tool that automatically detects significant (50 percent and over) ...
... Medical, Inc., a private sports medicine device company specializing ... immediately, David B. Springer will succeed James Hart as ... Executive Chairman due to health reasons. Hart, ... CEO since the company,s inception in 2005, will continue ...
Cached Medicine Technology:Rcadia COR Analyzer System Receives Expanded FDA Clearance to Rule Out Coronary Artery Disease in Coronary Branch Vessels 2Cayenne Medical, Inc. Appoints David B. Springer President & CEO 2Cayenne Medical, Inc. Appoints David B. Springer President & CEO 3
(Date:7/31/2014)... Most mommy blogs are simple family journals, ... to attract all mothers from all walks of life. ... whether its high fashion or child rearing. When Felicia ... the Internet was so segmented. “I found myself visiting ... and then search Google to get information on another. ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 A ... Music” EXPO in Hollywood introduced country artist/writer-producer Jimmy ... products for musicians. Etymotic is an innovator in ... Earplugs. Since their introduction in 2012, Etymotic’s Music•PRO® ... adapting to unsafe sound levels and restoring natural ...
(Date:7/31/2014)... (HealthDay News) -- Transplant surgeons often feel emotionally ... burnout, a new study suggests. Nearly half ... having a low sense of personal accomplishment and ... exhausted, researchers found. "Burnout is common in ... co-author Dr. Marwan Abouljoud, director of the Henry ...
(Date:7/31/2014)... Joseph M. Lee, M.D., M.S., R.P.V.I, has ... leading provider of quality cardiovascular and internal medicine services ... Lee is a board certified cardiologist with a focus ... to his position at CDHV, Dr. Lee is an ... University Medical Center. Dr. Lee is board certified in ...
(Date:7/31/2014)... Women in the Los Angeles area ... financial future. The Independent Woman , a leader ... 6 upcoming Los Angeles area events. , These ... input from Kim Kiyosaki, a successful investor, entrepreneur, and ... is passionate about women’s financial education. , Now, the ...
Breaking Medicine News(10 mins):Health News:Mommylish Launches Its Website 2Health News:Country Star Jimmy Robbins Now Using Etymotic’s MusicPRO Electronic Earplugs 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2
... HealthDay Reporter , MONDAY, May 2 (HealthDay News) ... infants is a surprisingly common practice, new research finds, but ... babies. The study, conducted by the U.S. Food ... are given botanical supplements or teas during their first year ...
... long sought a way to directly measure the brain,s temperature ... developed a way to get the brain,s precise temperature with ... a patient,s head, according to findings presented May 1 at ... "This is the first time that anyone has presented ...
... all counts, the 54-year-old man who collapsed on a ... died. He,d suffered a heart attack, and even though ... shocks with a defibrillator, the man was without a ... cardiac arrest ( http://www.mayoclinic.org/heart-attack/ ), reported first in ...
... , MONDAY, May 2 (HealthDay News) -- Exercising ... finds. The researchers looked at students in grades 1 ... who took part in a program that incorporated physical activity ... a week. Before the study, the students had 40 minutes ...
... have shown that blood-thinning medications, such as aspirin, can ... rising prostate-specific antigen (PSA) levelthe risk of metastasis and ... although very telling, have all emphasized the need for ... Cancer Center having concluded the largest study on this ...
... April 30 (HealthDay News) -- A new study finds that ... may predict increased arterial stiffness, which is associated with cardiovascular ... to pump blood and are also associated with a buildup ... flow and lead to a heart attack. In this ...
Cached Medicine News:Health News:Study Questions Giving Babies Botanical Supplements, Teas 2Health News:Study Questions Giving Babies Botanical Supplements, Teas 3Health News:Researchers develop device to measures brain temperature non-invasively 2Health News:Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes 2Health News:Exercising While Learning Boosts Test Scores, Study Finds 2Health News:Researchers find that aspirin reduces the risk of cancer recurrence in prostate cancer patients 2
... the state of the art product for ... articular surfaces does not restrict natural movement, ... a wide area of contact between the ... of cement create a homogeneous cement mantle ...
... The TC-PLUS Solution tricompartmental total knee ... with knee arthroplasty. State-of-the-art design and manufacturing ... achieve optimum biomechanical function as well as ... polyethylene tibial insert to keep wear to ...
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The modern design allows extremely sparing resections. The components exhibit an anatomical geometry t...
... System is a long term, quality solution ... in both posterior stabilized and anatomically correct ... provides the flexibility needed to address patients' ... of identification keeps the user in mind ...
Medicine Products: